Regeneron Pharma (REGN) Tops Q3 EPS Views; Raises FY12 EYLEA Net Sales Outlook
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q3 EPS of $1.89, $0.93 better than ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
